Abstract
No public abstract is available from the verified source records.
Maike Scherf-Clavel
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local citing links have been materialized yet.
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants
10.1002/cpt.2903 · 2023
Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and UK
10.1016/s2215-0366(26)00238-5 · 2026
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
10.1111/j.1365-2710.2006.00763.x · 2006
Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders
10.1080/15622975.2024.2321553 · 2024
Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study
10.1007/s11096-023-01588-8 · 2023
The relevance of integrating CYP2C19 phenoconversion effects into clinical pharmacogenetics
10.1055/a-2248-6924 · 2024
Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder
10.4088/jcp.08m04773blu · 2010
Effects of pharmacokinetic gene variation on therapeutic drug levels and antidepressant treatment response
10.1055/a-1872-0613 · 2022
Effects of pharmacogenetic screening for CYP2D6 among elderly starting therapy with nortriptyline or venlafaxine: a pragmatic randomized controlled trial (CYSCE trial)
10.1097/jcp.0000000000001129 · 2019
Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review
10.1002/cpt.2754 · 2022
No additional external references are available.